Ignite Creation Date:
2025-12-24 @ 10:53 PM
Ignite Modification Date:
2025-12-30 @ 8:21 PM
Study NCT ID:
NCT04984369
Status:
UNKNOWN
Last Update Posted:
2023-08-21
First Post:
2021-07-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Sponsor:
Shanghai Henlius Biotech
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
HLX208-mCRC201（BECOMES）
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None